Press release
CD40 Ligand (CD40L) Antibody Market Growth Accelerates: Strategic Forecast Predicts $1.01 Billion by 2029
CD40 Ligand (CD40L) Antibody
What Will the CD40 Ligand (CD40L) Antibody Industry Market Size Be by 2025?
In recent years, the market for CD40 ligand (CD40L) antibody has experienced substantive growth. It is estimated to rise from a value of $0.63 billion in 2024 to $0.69 billion in 2025, projecting a compound annual growth rate (CAGR) of 9.7%. This notable increase during the historical period can be attributed to factors such as the growing prevalence of autoimmune diseases, increased demand for cancer-specific treatments, expanded immune modulation research, novel biologics receiving regulatory approval, a surge in healthcare expenditure, and the growing inclination towards personalized medicine.
What's the Long-Term Growth Forecast for the CD40 Ligand (CD40L) Antibody Market Size Through 2029?
In the next few years, the market size of the CD40 ligand (CD40L) antibody is anticipated to witness significant growth, expanding to "$1.01 billion by 2029 with a compound annual growth rate (CAGR) of 10.0%. The surge in the projected timeframe can be credited to the increased acceptance of personalized medicine, booming investments in research for autoimmune and transplant procedures, mounting regulatory endorsements for new treatments, growing cognizance regarding the benefits of CD40L antibody in organ transplantation, and proliferating clinical trials for immunosuppression. Key trends driving the forecast period encompass advancements in antibody engineering, formulation of bispecific antibodies for focussed therapies, groundbreaking innovations in delivery techniques, developments in combination therapies, strides in personalized medicine, and leaps in the creation of biomarkers for improved patient selection.
View the full report here:
https://www.thebusinessresearchcompany.com/report/cd40-ligand-cd40l-antibody-global-market-report
What Are the Key Growth Drivers Fueling the CD40 Ligand (CD40L) Antibody Market Expansion?
An upsurge in autoimmune diseases is predicted to fuel the CD40 ligand (CD40L) antibody market's expansion. Autoimmune diseases, including rheumatoid arthritis, lupus, and type 1 diabetes, occur when the body's immune system targets its cells, inflicting harm. The increasing manifestation of these disorders can be traced back to factors such as environmental influences, genetic factors, changes in lifestyle, and heightened diagnostic awareness. These elements collectively result in higher detection rates and prevalence. CD40 Ligand (CD40L) antibodies are gaining traction as a promising treatment strategy for autoimmune diseases by regulating the immune system's hyperactive response. For example, the Australian Institute of Health and Welfare reported in July 2024 that about 514,000 Australians (2.0% of the population) were suffering from rheumatoid arthritis, a form of autoimmune disease, in 2022. This affected 2.5% of women and 1.6% of men. Consequently, the proliferating rate of autoimmune diseases propels the growth of the CD40 ligand (CD40L) antibody market.
Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21132&type=smp
What Are the Key Trends Driving CD40 Ligand (CD40L) Antibody Market Growth?
Leading companies in the CD40 ligand (CD40L) antibody market are concentrating their efforts on progressing clinical research and broadening their therapeutic applications. Clinical trials are systemic experiments to assessing the safety, effectiveness, and best use of a medical intervention or treatment. For instance, Eledon Pharmaceuticals Inc., a biotech company based in the US, disclosed in September 2023 that they are utilizing the anti-CD40L antibody, Tegoprubart, in a clinical trial post the second-ever genetic pig heart transplant. The trial is aimed at evaluating its function in preventing the rejection of the organ and expanding the potential therapeutic applications in organ transplantation. Additionally, Tegoprubart exhibits potential in treating autoimmune diseases through immune response regulation.
How Is the CD40 Ligand (CD40L) Antibody Market Segmented?
The cd40 ligand (cd40l) antibody market covered in this report is segmented -
1) By Type: Monoclonal Antibody, Polyclonal Antibody
2) By Application: Flow Cytometry, Enzyme-Linked Immunosorbent Assay (ELISA), Western Blot, Immunoprecipitation, Immunofluorescence, Other Applications
3) By End-User: Hospitals, Research Institutes, Specialty Clinics, Other End-Users
Subsegments:
1) By Monoclonal Antibody: Fully Human Monoclonal Antibodies, Humanized Monoclonal Antibodies, Chimeric Monoclonal Antibodies
2) By Polyclonal Antibody: Rabbit Polyclonal Antibodies, Goat Polyclonal Antibodies, Mouse Polyclonal Antibodies
Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=21132&type=smp
Which Companies Are Leading the Charge in CD40 Ligand (CD40L) Antibody Market Innovation?
Major companies operating in the CD40 ligand (CD40L) antibody market are Thermo Fisher Scientific Co. Ltd., Amgen Inc., Bio-Rad Laboratories Inc., Bio-Techne Corporation, Kiniksa Pharmaceuticals Ltd., BioLegend, Cytek Biosciences Inc., Sino Biological Inc., ACROBiosystems, Elabscience Biotechnology Inc., Cayman Chemical, Eledon Pharmaceuticals, Cell Signaling Technology, Enzo Biochem, GeneTex, GeminiBio, Creative Biolabs, BPS Bioscience Inc., LSBio, MyBiosource Inc., Boster Biological Technology, Bio X Cell, Assay Genie, Abeomics, Leinco Technologies Inc.
Which Regions Are Leading the Global CD40 Ligand (CD40L) Antibody Market in Revenue?
North America was the largest region in the CD40 ligand (CD40L) antibody market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the CD40 ligand (CD40L) antibody market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21132
This Report Supports:
1.Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2.Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3.Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4.Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.
Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.
Contact Us
Saumya Sahey
Europe: +44 7882 955267,
Asia: +44 7882 955267 & +91 8897263534,
Americas: +1 310-496-7795
Email: saumyas@tbrc.info
Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release CD40 Ligand (CD40L) Antibody Market Growth Accelerates: Strategic Forecast Predicts $1.01 Billion by 2029 here
News-ID: 4185099 • Views: …
More Releases from The Business Research Company
Impact Of Rising Pneumonia Cases On The Growth Of Market: Strategic Insights Dri …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
How Large Will the Pulmonary Or Respiratory Drug Delivery Market Size By 2025?
The market size of pulmonary or respiratory drug delivery has seen robust growth over the past few years. It is projected to expand from $69.83 billion in 2024 to $75.67 billion in 2025, exhibiting a compound…
Future of the Lung Cancer Drugs Market: Trends, Innovations, and Key Forecasts T …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
Lung Cancer Drugs Market Size Growth Forecast: What to Expect by 2025?
Rapid expansion has been observed in the lung cancer drugs market size in the past few years. The market, which is predicted to escalate from $47.65 billion in 2024 to $52.98 billion in 2025, is expected to…
Personalized Vitamin Products Market Poised to Hit $18.06 Billion by 2029 with A …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
Personalized Vitamin Products Market Size Growth Forecast: What to Expect by 2025?
The market size for custom-tailored vitamin products has witnessed significant expansion in the past few years. The expected growth trajectory is from $9.6 billion in 2024 to $10.86 billion in 2025, presenting a compound annual growth rate…
Rising Demand For Personalized Care Fueling The Growth Of The Market Due To Enha …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
What Is the Expected CAGR for the Nocturnal Enuresis Medication Market Through 2025?
The market for nocturnal enuresis drugs has seen substantial growth in the past few years. The market is projected to surge from $1.53 billion in 2024 to $1.63 billion in 2025, with a compound annual growth…
More Releases for CD40
CD40 Ligand (CD40L) Antibody Market Size Projected To Reach 1.03 Billion By 2034 …
We've updated all our reports with current data on tariff changes, trade developments, and supply chain shifts affecting key industries.
What Is the Projected Growth of the CD40 Ligand (CD40L) Antibody Market?
The market size for the CD40 Ligand (CD40L) antibody has experienced fast growth in recent years, expanding from $0.63 billion in 2024 to a projected size of $0.70 billion in 2025 with a compound annual growth rate of 10.7%. The…
CD40 Ligand (CD40L) Antibody Market is expected to grow at USD 2.5 billion by 20 …
"The CD40 Ligand (CD40L) antibody market is projected to reach a value of approximately $1.2 billion in 2024, driven by increased autoimmune disease prevalence and advancements in targeted therapies. The market is expected to grow significantly, with a projected value of $2.5 billion by 2034, reflecting a robust Compound Annual Growth Rate (CAGR) of around 7.7% during the 2025-2034 forecast period."
Exactitude Consultancy., Ltd. released a research report titled "CD40 Ligand…
Comprehensive CD40 Ligand (CD40L) Antibody Market Insights: Forecasting Size, Gr …
What market dynamics are playing a key role in accelerating the growth of the cd40 ligand (cd40l) antibody market?
The rising incidence of autoimmune disorders is expected to drive the growth of the CD40 ligand (CD40L) antibody market. Autoimmune disorders, in which the immune system attacks the body's tissues, are becoming more prevalent due to environmental factors, genetic predisposition, and increased awareness. CD40L antibodies are a promising therapeutic option for treating…
CD40 Ligand Market worth $1,012.29 million by 2030, growing at a CAGR of 5.47% - …
The "CD40 Ligand Market by Type (Monoclonal Antibody, Polyclonal Antibody), Application (Autoimmune Disease Treatment, Immunotherapy, Vaccine Development), End-Users - Global Forecast 2024-2030" report has been added to 360iResearch.com's offering.
Request a Free Sample Report @ https://www.360iresearch.com/library/intelligence/cd40-ligand
CD40 Ligand (CD40L), also known as CD154, is a protein crucial for immune system regulation, primarily expressed on activated T cells, and interacts with the CD40 receptor on B cells, dendritic cells, macrophages, and other antigen-presenting…
Insights on the CD40 Ligand Market to 2022 | Industry Statistics, Emerging Deman …
The global CD40 Ligand market is anticipated to grow at a significant CAGR during the forecast period (2022-2028). CD154, also known as CD40 ligand or CD40L, is a member of the TNF superfamily of molecules that is largely expressed on activated T cells. It attaches to CD40 (protein) on antigen-presenting cells (APC), resulting in a variety of consequences depending on the kind of target cell.CD40 expression has also been found…
CD40 Ligand Market 2022 | Detailed Report
The CD40 Ligand research report provides a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources. The data thus presented is reliable, comprehensive and the result of extensive research both primary and secondary. The analysts have presented the various facets of the market with a particular focus on identifying the key industry influencers. Moreover, the data underlines the primary and secondary drivers,…
